Related Experiment Video
Updated: Aug 2, 2025
07:55
Pancreatic Tissue-Derived Extracellular Matrix Bioink for Printing 3D Cell-Laden Pancreatic Tissue Constructs
Published on: December 13, 2019
11.0K
Three-dimensional bioprinting of functional β-islet-like constructs.
Shahram Parvaneh1,2,3,4, Lajos Kemény1,3,5, Ameneh Ghaffarinia5
1Regenerative Medicine and Cellular Pharmacology Laboratory (HECRIN), Department of Dermatology and Allergology, University of Szeged, Koranyi fasor 6., H 6720, Szeged, Hungary.
International Journal of Bioprinting
|April 17, 2023
Summary
Bioprinting offers a novel solution for Type 1 diabetes by creating artificial pancreatic islets. This approach uses stem cells and advanced biomaterials to overcome donor shortages and immune rejection challenges.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Immunology
Background:
- Type 1 diabetes involves autoimmune destruction of pancreatic beta cells, leading to insulin deficiency and severe long-term complications.
- Current treatments like pancreas or islet transplantation are limited by donor scarcity and the need for lifelong immunosuppression.
- Hydrogel encapsulation of islets shows promise but faces challenges like hypoxia within the core of the capsules.
Purpose of the Study:
- To explore the potential of bioprinting technology for fabricating functional bioartificial pancreatic islet tissue.
- To address limitations of current therapies, including donor scarcity and immune rejection.
- To investigate strategies for enhancing the survival and function of bioprinted pancreatic constructs.
Main Methods:
- Utilizing multipotent stem cells as a source for generating functional beta cells or islet-like tissue.
- Employing bioprinting technology to arrange cells, biomaterials, and bioactive factors into a bioink.
- Incorporating supporting cells (endothelial, regulatory T, mesenchymal stem cells) to promote vasculogenesis and immune regulation.
- Developing scaffolds with oxygen-releasing or angiogenesis-enhancing biomaterials.
Main Results:
- Bioprinting enables the precise spatial arrangement of cellular components to mimic native pancreatic islet architecture.
- The use of stem cells provides a scalable source for beta cell generation, potentially alleviating donor limitations.
- Incorporation of supporting cells and advanced biomaterials can improve construct survival and function by mitigating hypoxia and promoting vascularization.
Conclusions:
- Bioprinting holds significant promise for creating bioartificial pancreatic islets to treat Type 1 diabetes.
- Addressing hypoxia and immune rejection through biomaterial design and cell selection are crucial for therapeutic success.
- This innovative approach offers a potential alternative to traditional transplantation, improving patient outcomes and quality of life.
